{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:11:37Z","timestamp":1762866697623},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2015,9,15]]},"DOI":"10.1093\/cid\/civ535","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T13:19:03Z","timestamp":1440681543000},"page":"S79-S86","source":"Crossref","is-referenced-by-count":15,"title":["The Role of Telavancin in Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia"],"prefix":"10.1093","volume":"61","author":[{"given":"Christian E.","family":"Sandrock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew F.","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,8,27]]},"reference":[{"key":"2015082705480071000_61.suppl_2.S79.1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31822d7913"},{"key":"2015082705480071000_61.suppl_2.S79.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"2015082705480071000_61.suppl_2.S79.3","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2014.282"},{"key":"2015082705480071000_61.suppl_2.S79.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-014-3564-5"},{"key":"2015082705480071000_61.suppl_2.S79.5","doi-asserted-by":"publisher","DOI":"10.1086\/678594"},{"key":"2015082705480071000_61.suppl_2.S79.6","unstructured":"VIBATIV (telavancin) Prescribing Information. Theravance Biopharma Antibiotics, Inc. December 2014. Accessed 28 January 2015."},{"key":"2015082705480071000_61.suppl_2.S79.7","unstructured":"Clinigen Healthcare, Ltd. Vibativ: summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001240\/WC500115364.pdf . Accessed 19 March 2015."},{"key":"2015082705480071000_61.suppl_2.S79.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-07"},{"key":"2015082705480071000_61.suppl_2.S79.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1847-6"},{"key":"2015082705480071000_61.suppl_2.S79.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-07"},{"key":"2015082705480071000_61.suppl_2.S79.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04052-14"},{"key":"2015082705480071000_61.suppl_2.S79.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.12.011"},{"key":"2015082705480071000_61.suppl_2.S79.13","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ534","article-title":"Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480071000_61.suppl_2.S79.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.08.010"},{"key":"2015082705480071000_61.suppl_2.S79.15","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq335"},{"key":"2015082705480071000_61.suppl_2.S79.16","doi-asserted-by":"crossref","DOI":"10.2217\/fmb.15.53","article-title":"A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections","author":"Chan","year":"2015","journal-title":"Future Microbiol"},{"key":"2015082705480071000_61.suppl_2.S79.17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl424"},{"key":"2015082705480071000_61.suppl_2.S79.18","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.979789"},{"key":"2015082705480071000_61.suppl_2.S79.19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4344-4346.2005"},{"key":"2015082705480071000_61.suppl_2.S79.20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm417"},{"key":"2015082705480071000_61.suppl_2.S79.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00062-10"},{"key":"2015082705480071000_61.suppl_2.S79.22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"2015082705480071000_61.suppl_2.S79.23","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ536","article-title":"Telavancin hospital-acquired pneumonia trials: impact of gram-negative infections and inadequate gram-negative coverage on clinical efficacy and all-cause mortality","author":"Lacy","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480071000_61.suppl_2.S79.24","unstructured":"Center For Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for Industry. Hospital-acquired bacterial pneumonia and ventilator associated bacterial pneumonia: developing drugs for treatment. Draft guidance, May 2014. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM234907.pdf. Accessed 9 March 2015."},{"key":"2015082705480071000_61.suppl_2.S79.25","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ522","article-title":"Telavancin: the long and winding road from discovery to FDA approvals and future directions","author":"Wenzler","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480071000_61.suppl_2.S79.26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02330-13"},{"key":"2015082705480071000_61.suppl_2.S79.27","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000277042.31524.66"},{"key":"2015082705480071000_61.suppl_2.S79.28","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0b013e3181cc0418"},{"key":"2015082705480071000_61.suppl_2.S79.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.06.003"},{"key":"2015082705480071000_61.suppl_2.S79.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0094OC"},{"key":"2015082705480071000_61.suppl_2.S79.31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01615-10"},{"key":"2015082705480071000_61.suppl_2.S79.32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.1.213"},{"key":"2015082705480071000_61.suppl_2.S79.33","doi-asserted-by":"publisher","DOI":"10.1086\/518460"},{"key":"2015082705480071000_61.suppl_2.S79.34","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S25930"},{"key":"2015082705480071000_61.suppl_2.S79.35","unstructured":"Cubist Pharmaceuticals. Cubicin (daptomycin for injection), prescribing information. Available at: http:\/\/cubicin.com\/ . Accessed 7 April 2015."},{"key":"2015082705480071000_61.suppl_2.S79.36","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg020"},{"key":"2015082705480071000_61.suppl_2.S79.37","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R386"},{"key":"2015082705480071000_61.suppl_2.S79.38","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ528","article-title":"Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment","author":"Cardona","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480071000_61.suppl_2.S79.39","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ523","article-title":"Evolving resistance among gram-negative pathogens","author":"Munita","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2015082705480071000_61.suppl_2.S79.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.08.005"},{"key":"2015082705480071000_61.suppl_2.S79.41","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir935"},{"key":"2015082705480071000_61.suppl_2.S79.42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6364"},{"key":"2015082705480071000_61.suppl_2.S79.43","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks495"},{"key":"2015082705480071000_61.suppl_2.S79.44","doi-asserted-by":"publisher","DOI":"10.1086\/313440"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_2\/S79\/1115128\/civ535.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:26:07Z","timestamp":1503447967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/civ535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,27]]},"references-count":44,"journal-issue":{"issue":"suppl 2","published-online":{"date-parts":[[2015,8,27]]},"published-print":{"date-parts":[[2015,9,15]]}},"alternative-id":["10.1093\/cid\/civ535"],"URL":"https:\/\/doi.org\/10.1093\/cid\/civ535","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,27]]}}}